After a PSA test Jeff Nelson’s knew he had a prostate cancer and he had to move quickly to treat it. A prostate cancer specialist, Edward M. Uchio, recommended him to use a technique called MRI fusion biopsy. The fusion between MRI and biopsies allows to know the area to treat.
Uchio and Nelson discussed his options, to choose the best treatment. Nelson chose the Focal One treatment because it was non-invasive (no needles and no scalpels) and accurate to target the prostate cancerous tissue. he was able to come back home the same day of the treatment.
According to Dr. Uchio, traditional treatments for prostate cancer have benefits but also risks and focal HIFU technology may offer a safer way. Indeed this method is expected to lower potential side effects.
In february 2019 John Wayne Cancer Institute (JWCI) at the Providence Saint John’s Health Center acquired Focal One. Focal One is a medical device for performing a targeted and non-invasive ablation of diseased prostate tissue. Mehran Movassaghi, M.D, MBA, Director of Pacific Men’s Health at Providence Saint John’s, was asked to discuss about it.
Focal One allows the urologist to precisely target the portion of the prostate with the disease. As a consequence, only the prostate areas harboring cancer are treated, living healthy tissue intact.
There are 3 ways to manage prostate cancer: active surveillance, localized and complete treatment. According to Dr. Mehran Movassaghi, “Focal One fills a significant void between active surveillance and radical treatments.”